Compare KB Financial Group, Inc. (KB) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KB Financial Group, Inc. vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? KB Financial Group, Inc. trades at $115.32 (market cap $42.72B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: KB Financial Group, Inc. is far larger — about 43.9× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and KB Financial Group, Inc. pays a 2.73% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold KB Financial Group, Inc. for 33 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| KB | MRVI | |
|---|---|---|
Market Cap | $42.72B | $972.90M |
Volume | 268,131 | 4,325,710 |
Sector | Financials | Health |
52-Week High | $132.88 | $9.00 |
52-Week Low | $80.15 | $2.83 |
Typical Hold Time | 33 Days | 0 Days |
Enterprise Value | $214.27T | $1.08B |
Dividend Yield | 2.73% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KB Financial Group (KB) trades at $117.00, down 4.08% on the day, with bearish technical signals from moving averages. Fundamentally, the company shows strong profitability with 28.09% net income margin and consistent earnings beats, though valuation metrics like P/E of 9.65 suggest potential undervaluation. Recent news highlights institutional interest and positive momentum coverage from financial media.
The stock presents a value opportunity with attractive valuation ratios and solid earnings growth, but faces near-term technical headwinds and mixed analyst sentiment. Key risks include market volatility and execution challenges in the competitive banking sector, while institutional accumulation and strong South Korean market performance provide supportive tailwinds.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About KB Financial Group, Inc.
KB Financial is the parent company of KB Kookmin Bank, Korea's largest commercial bank, with a 13.1% share of loans as of 2021. Its predecessor banks were established in the 1960s as government policy banks and privatized in the 1990s. Its credit card subsidiary KB Kookmin Card is the number-three player behind Shinhan Card and Samsung Card. KB has in recent years expanded its nonbank business by buying LIG Insurance and Hyundai Securities, making KB a top-five player in nonlife insurance and in securities, and most recently by buying Prudential Life Insurance Korea. It also has KB Capital, which provides leasing and installment finance.
Read more on KB →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
